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Abnormal arterial-venous fusions 
and fate specification in mouse 
embryos lacking blood flow
Jennifer J. Hwa, Nathan Beckouche, Lawrence Huang, Yoseph Kram, Henrik Lindskog &  
Rong A. Wang
The functions of blood flow in the morphogenesis of mammalian arteries and veins are not well 
understood. We examined the development of the dorsal aorta (DA) and the cardinal vein (CV) in Ncx1 
−/− mutants, which lack blood flow due to a deficiency in a sodium calcium ion exchanger expressed 
specifically in the heart. The mutant DA and CV were abnormally connected. The endothelium of the 
Ncx1−/− mutant DA lacked normal expression of the arterial markers ephrin-B2 and Connexin-40. 
Notch1 activation, known to promote arterial specification, was decreased in mutant DA endothelial 
cells (ECs), which ectopically expressed the venous marker Coup-TFII. These findings suggest that flow 
has essential functions in the DA by promoting arterial and suppressing venous marker expression. In 
contrast, flow plays a lesser role in the CV, because expression of arterial-venous markers in CV ECs was 
not as dramatically affected in Ncx1−/− mutants. We propose a molecular mechanism by which blood 
flow mediates DA and CV morphogenesis, by regulating arterial-venous specification of DA ECs to 
ensure proper separation of the developing DA and CV.
The circulatory system is the first organ to emerge during embryonic development because the embryo grows 
in size and must deliver an adequate blood supply to its tissues. The development of the vascular system is a 
fundamental process that requires arterial-venous (AV) fate specification in the formation of arteries and veins. 
In mammalian embryos, the first artery/vein pair to form is the parallel dorsal aorta (DA) and the cardinal vein 
(CV), which, respectively, carry blood away from and return blood back to the heart. In the mouse embryo, the 
DA is assembled first from the de novo differentiation of angioblast precursors beginning around 3 somite stage 
(ss), embryonic day (E) 8.0, whereas the CV arises about half a day later1–3. The relative simplicity of this first 
artery/vein pair provides an excellent model for studying artery and vein morphogenesis.
Blood flow plays a critical, yet poorly understood, role in the formation of blood vessels, and in particular the 
formation of the DA and CV. The heartbeat in the mouse embryo begins at approximately 3ss and blood flow is 
initiated at around 6–7ss4. In mice lacking the giant muscle protein gene titin, which is expressed in cardiac and 
skeletal muscle and required for sarcomere formation and assembly, the embryonic heart displays only weak 
spontaneous contractions and never develops a regular contractile rhythm, leading to a delayed onset of blood 
circulation until after E9.55,6. Although titin is not expressed in the vasculature, the lumen of the DA in these 
mutants was variable and irregularly sized at E8.5. This finding suggests that compromised blood flow affects the 
morphogenesis of the DA and CV. However, the precise function of flow on the development of the DA and CV 
and the mechanisms underlying its effects remain to be elucidated.
Other mouse flow mutants have also been used to study the requirement of blood flow on mammalian vas-
cular development. For example, embryos with a deficiency in mlc2a, a myosin light chain isoform expressed in 
cardiac muscle, have impaired atrial contractility, and thus, impaired blood flow patterns. These mutants display 
disorganization in the cranial and intersomitic vessels4,6,7. Another widely used model is the Ncx1−/− mutant, 
which is defective in a sodium calcium ion exchanger expressed specifically in the embryonic heart, and never 
develops a heartbeat nor blood flow8–12. Ncx1 expression has been shown to be restricted to the heart throughout 
early embryogenesis until E11.011–13, ensuring that defects seen outside the heart before this stage are a result of 
the lack of blood flow and not a direct effect of gene function. These mutants have been previously used to demon-
strate the essential role of blood flow in hematopoietic stem cell development8–10,14. However the development 
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of the DA and CV in Ncx1−/− mutants has not been reported. These mutants provide excellent genetic tools for 
ascertaining the requirement of blood flow on blood vessel morphogenesis.
Genes in the Notch and the EphB4/ephrin-B2 signaling pathways have been implicated in formation of the 
mammalian DA and CV15–18. Our lab has reported that DA and CV formation may occur in a coordinated man-
ner involving the distribution of endothelial cells (ECs) between the two vessels19,20. In addition, mutants in the 
Notch and the EphB4/ephrin-B2 signaling pathways were found to contain AV shunts, or AV fusions, abnormal, 
direct connections between the artery and vein that led to a short circuit in circulation21. However, how blood 
flow affects the expression of these genes in the developing DA and CV is not well understood.
Recent studies have begun to shed light on genes regulated by blood flow during artery and vein morphogen-
esis in the developing mouse embryo. Cultured embryos with physical ablation of blood flow were generated ex 
vivo by snipping the yolk sac vessel inlets to the heart prior to the onset of blood flow to stop blood circulation. 
These embryos exhibit defects in the vasculature of the extra-embryonic yolk sac, which remains as a primitive 
capillary-like plexus and fails to remodel into a mature hierarchical artery-vein tree4,22. In situ hybridization has 
shown that these cultured embryos lack expression of both Connexin-40, an arterial specific marker, as well as 
Notch1, which is expressed arterially to promote the arterial EC fate, in the DA1,23,24. However, whether DA and 
CV morphogenesis is affected by physical ablation of blood flow is unknown.
To investigate the role of blood flow in DA and CV development in utero, we examined their formation in the 
Ncx1−/− mutant. By imaging DA and CV development in whole mount embryos, we show that in the absence 
of flow, fusions are found between the DA and CV, suggesting that blood flow plays a crucial role in the proper 
separation of this artery and vein pair. Fusions were accompanied by defects in arterial-venous specification of 
the DA, with loss of arterial markers along with ectopic expression of a venous marker. This study suggests a 
potential molecular mechanism for how blood flow mediates DA and CV formation, whereby flow promotes 
arterial and represses venous fate specification, which then ensures the proper separation of the two vessels dur-
ing development.
Results
Abnormal fusions between the DA and CV in Ncx1−/− mutant embryos lacking blood flow. 
Although previous studies have shown a role for blood flow in formation of the mouse embryonic vasculature, 
including in the DA6,7, the precise role of flow in the morphogenesis of the DA and the CV is still not completely 
understood. To gain further insight into this process, we examined DA and CV development in embryos that lack 
blood flow, using the Ncx1−/− mutant.
To examine DA and CV morphogenesis in the Ncx1−/− mutant, we imaged the DA and CV in whole mount 
embryos by two-photon microscopy, which allowed us to reconstruct vessel morphology in detail. At 15–17ss 
(E9.0), in lateral views of the embryo in the region adjacent to the heart (Fig. 1A,E), or in optical cross sections 
through the embryo (Fig. 1B–D,F–H), the DA and CV in control mice were well separated vessels with distinct 
lumens. In all three Ncx1−/− mutants analyzed, there were abnormal fusions, where the two vessels appeared to 
be merged together (Fig. 1G,H, yellow arrowhead; average of 8.3 fusions per embryo). Furthermore, the DA in 
the Ncx1−/− mutant also appeared to be irregular, with the vessel larger at locations where fusions occurred and 
smaller in others, which suggested that DA irregularity may be related to the abnormal fusions. These results 
demonstrate that proper formation of the DA and CV was compromised, and abnormal fusions occurred between 
the two vessels in Ncx1−/− mutant embryos lacking blood flow.
Abnormal fusions between the DA and CV were present shortly after the normal onset of blood 
flow. If the DA and CV fusions found in Ncx1−/− mutants were a direct result of the lack of blood flow, we 
would expect that fusions would be apparent soon after the stage when flow normally begins, which is around 
6–7ss4. Therefore, we next examined the DA and CV shortly thereafter, at 9–11ss (E8.0–8.5). At this stage, very 
thin connections between the DA and the CV can be observed in control embryos, as previously reported25. 
However, 10 out of 16 Ncx1−/− mutants analyzed at this stage already displayed abnormal DA and CV fusions 
(Fig. 2E–H, yellow arrowhead; average of 3.5 fusions per embryo), which were not found in control embryos 
(Fig. 2A–D). Irregularity in the DA was also observed at this stage in the mutants (Fig. 2E,G, note the wider DA in 
the region where fusion is located). Therefore, the presence of the DA and CV defects and the initiation of blood 
flow in the embryo appeared to be correlated, supporting the hypothesis that flow is required to prevent improper 
fusions between the two vessels.
Endothelial cells of the Ncx1−/− mutant DA lacked expression of arterial markers. The aberrant 
fusions between the DA and CV in Ncx1−/− mutants suggested that their ECs were not restricted to the appropri-
ate vessel. To test whether one underlying cause was a loss of proper arterial-venous identity in DA and CV ECs, 
we first examined arterial fate specification in the DA by looking at expression of the canonical arterial fate marker 
ephrin-B2, using the EfnB2H2BGFP reporter line, which contains a nuclear GFP (H2BGFP) transgene knocked 
into the EfnB2 gene locus26. At 15–17ss, in control embryos, nearly all ECs of the DA were EfnB2GFP positive 
(96 ± 3%, Fig. 3A,B,I), whereas in the Ncx1−/− mutant, very few DA ECs were (7 ± 5%, p < 0.001, Fig. 3C,D,I). The 
average level of EfnB2GFP per cell in the DA was also much decreased in the Ncx1−/− mutant compared to con-
trols (1.7 ± 0.1 vs. 6.9 ± 1.0, p < 0.001, Fig. 3J). ephrin-B2 is known to be expressed in the DA but not the CV18, 
and EfnB2GFP expression was not observed in the CV of control or mutant embryos (Fig. 3E–H,I,J). To confirm 
that DA ECs in the Ncx1−/− mutant lacked proper arterial specification, we looked at a second arterial marker, 
the gap junction protein Connexin-40 (Cx40). In control embryos, Cx40 was expressed in the DA but not the CV 
(Fig. 4A,B,E,F,I), as was shown previously1,20. Consistent with the findings from examining EfnB2GFP expression, 
DA expression of Cx40 was also lost in Ncx1−/− mutants (Fig. 4C,D,G–I). Therefore, these results suggested that 
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the DA and CV fusions seen in Ncx1−/− mutants were accompanied by a lack of arterial specification in ECs of 
the DA.
Increased arterial marker expression in the DA following the onset of blood flow was lost in 
Ncx1−/− mutants. We sought to examine in more detail the requirement of flow in arterial fate specification 
in DA ECs. If the onset of flow acts as a signal that contributes to the acquisition of arterial fate in ECs in the 
DA, we might expect arterial marker expression in DA ECs to increase following the onset of blood flow, in a 
flow-dependent manner.
To test this hypothesis, we analyzed EC expression of EfnB2GFP and Cx40 over time, beginning at the stage 
when blood flow is initiated (6–8ss), in control and Ncx1−/− mutant embryos. At this stage, EfnB2GFP expression 
was found in 27 ± 18% of DA ECs in control embryos. By 9–11ss, expression increased to 68 ± 23% of DA ECs, 
and by 15–17ss, nearly all DA ECs were EfnB2GFP positive (96 ± 3%, Fig. 5A). Average EfnB2GFP intensity per 
cell also increased over this time period (Fig. 5B), which, together with the previous findings, suggested that 
EfnB2GFP expression in DA ECs was correlated with the initiation of blood flow. Furthermore, this acquisi-
tion of EfnB2GFP expression was flow-dependent, as it was abrogated in the Ncx1−/− mutant (Fig. 5A,B). These 
Figure 1. Abnormal fusions between the Dorsal Aorta (DA) and Cardinal Vein (CV) in Ncx1−/− mutants. Two-
photon images of Control (A–D) and Ncx1−/− mutant (E–H) embryos at 15–17ss (E9.0) stained with PECAM-
1. (A,E) Lateral projection view of the DA and CV. (B–D,F–H) Optical cross sections taken at indicated 
positions. Red arrow, DA; Blue arrowhead, CV; Yellow arrowhead, DA-CV fusion. Scale bar: 100 um. n = 3 
embryos per genotype were analyzed.
www.nature.com/scientificreports/
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data, therefore, suggested that DA ECs acquired EfnB2GFP expression following the initiation of blood flow, and 
required flow to do so.
We found a similar result upon examining Cx40 expression in DA ECs. Cx40 intensity in the DA increased 
from 6–8ss to 15–17ss (1.35 ± 0.16 to 1.73 ± 0.15, p < 0.05), and this increase failed to occur in the Ncx1−/− 
mutant (Fig. 5C). However, the expression of the arterial marker Dll4 was not affected in mutant embryos (data 
not shown), consistent with previously published data1. Altogether, these results suggested that in the DA, arterial 
marker expression was correlated with the onset of blood flow, in a flow-dependent manner, suggesting a role for 
flow in acquisition of arterial fates of DA ECs, even if this was restricted to a subset of arterial markers.
Reduced Notch1 activity in endothelial cells of the DA in Ncx1−/− mutants. To investigate the 
molecular mechanism underlying the requirement of blood flow in arterial fate specification in the DA, we next 
examined the Notch pathway, which promotes arterial fates in endothelial cells and is required for arterial marker 
expression in the DA17,23. To determine whether Notch signaling may also be affected in Ncx1−/− mutants, we 
assayed Notch activity in the DA using an antibody against the cleaved, activated form of Notch1 (Notch1-ICD). 
Notch1-ICD staining was found in the DA in control embryos (Fig. 6A,B), but in Ncx1−/− mutants, Notch1-ICD 
intensity was significantly reduced in the DA (Fig. 6C,D,I, 2.2 ± 0.2 vs. 1.5 ± 0.1, p < 0.05). As expected, Notch1 
signaling did not appear to be activated in the CV (Fig. 6E-I). This is consistent with a previous study showing 
that Notch1 expression requires flow during development24.Therefore, our findings indicated that Notch1 was 
also activated in the DA in a flow-dependent manner, suggesting one potential molecular mechanism for the 
requirement of flow in arterial fate specification.
Figure 2. DA and CV fusions in the Ncx1−/− mutant were present at an embryonic stage shortly after the 
normal onset of blood flow. Two-photon images of Control (A–D) and Ncx1−/− mutant (E–H) embryos at 
9–11ss (E8.0–8.5) stained with PECAM-1. Red arrow, DA; Blue arrowhead, CV; Yellow arrowhead, DA-CV 
fusion. Scale bar: 100 um. n ≥ 8 embryos per genotype were analyzed.
www.nature.com/scientificreports/
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Expression of the venous marker Coup-TFII was mildly affected in endothelial cells of the CV in 
Ncx1−/− mutants. The results of our previous experiments showed that the DA and CV fusions in Ncx1−/− 
mutants were accompanied by loss of arterial fates in the DA, which supports the hypothesis that the fusions 
may result from the loss of proper arterial-venous identity that distinguishes DA and CV ECs. We next tested 
whether venous fate of CV ECs was similarly affected in Ncx1−/− mutants by examining expression of the venous 
marker Coup-TFII27. In control embryos, Coup-TFII was expressed in the CV (Fig. 7A,B). In Ncx1−/− mutants, 
the proportion of Coup-TFII expressing cells was slightly reduced, although most CV ECs retained Coup-TFII 
expression (98 ± 1% vs. 94 ± 2%, p < 0.05, Fig. 7C,D,I). Therefore, in contrast to arterial fate specification in the 
DA, venous fate specification in the CV was less affected in Ncx1−/− mutants lacking blood flow.
Ectopic expression of the venous marker Coup-TFII in endothelial cells of the DA in Ncx1−/− 
mutants. Although Coup-TFII expression was affected mildly in Ncx1−/− mutants in the CV, in the DA we 
were surprised to find ectopic Coup-TFII expression. In 15–17ss control embryos, only rare Coup-TFII positive DA 
ECs were found (4 ± 2%, Fig. 7E,F,I), as has been reported previously20. In Ncx1−/− mutants however, we found that 
approximately half of DA ECs expressed Coup-TFII (53 ± 10%, Fig. 7G,H,I), suggesting that flow was required to 
suppress ectopic expression of this venous marker in the DA. Therefore, our findings suggest a requirement for blood 
flow in DA EC fate specification, both for promoting arterial marker and for suppressing venous marker expression.
Figure 3. DA ECs lacked expression of the arterial marker ephrin-B2 in Ncx1−/− mutants. (A–H) EfnB2GFP 
expression at 15–17ss in ECs of control (A,B,E,F) and Ncx1−/− mutants (C,D,G,H) in the DA (A–D) and CV 
(E–H). Red, PECAM-1; Green, EfnB2GFP. Scale bar: 25 um. (I) Proportion of EfnB2GFP positive ECs in the 
DA and CV. (J) Average EfnB2GFP intensity per EC. ***P < 0.001. Average values  ±  s.d. are shown; n = 4 
embryos per genotype.
Figure 4. DA ECs in Ncx1−/− mutants also lacked expression of a second arterial marker, Connexin-40. (A–H) 
Cx40 expression at 15–17ss in ECs of control (A–B,E–F) and Ncx1−/− mutants (C,D,G,H) in the DA (A–D) and 
CV (E–H). Green, PECAM-1; Red, Cx40. Scale bar: 25 um. (I) Average Cx40 intensity (in PECAM1 positive 
area) in the DA and CV. ***P < 0.001. Average values  ±  s.d. are shown; n ≥ 4 embryos per genotype.
www.nature.com/scientificreports/
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No significant changes in the number of endothelial cells in the DA and CV of Ncx1−/− 
mutants. Our previous experiment showed that in Ncx1−/− mutants approximately half of DA ECs were 
Coup-TFII positive, whereas only rare Coup-TFII positive ECs were present in the DA in controls. To confirm 
Figure 5. Arterial marker expression in DA ECs increased at somite stages following the onset of blood flow, 
which was lost in the Ncx1−/− mutant. (A) Proportion of EfnB2GFP positive ECs at 6–8, 9–11, and 15–17ss in 
controls and Ncx1−/− mutants, in the DA and the CV. (B) Average EfnB2GFP intensity per EC in the DA and 
CV. (C) Average Cx40 intensity (in PECAM1 positive area) in the DA and CV. Statistical analysis was performed 
using an ANOVA with Bonferroni post test. *P < 0.05, **P < 0.01, ***P < 0.001. Average values  ±  s.d. are 
shown; n ≥ 3 embryos per genotype.
www.nature.com/scientificreports/
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that this was due to an increase in ectopic Coup-TFII expression in DA ECs, rather than redistribution of ECs 
from the CV, we counted the number of ECs in both the DA and the CV, in controls and Ncx1−/− mutants. 
In the DA, we found an average of 6.2 ± 0.6 ECs per vessel section in controls and 5.1 ± 1.1 ECs in Ncx1−/− 
mutants, a difference which was not statistically significant (Fig. 8A, p = 0.15). In the CV there were 6.6 ± 1.3 vs. 
4.8 ± 1.6 ECs in controls and Ncx1−/− mutants, respectively, which was also not a significant difference (Fig. 8A, 
p = 0.13). Importantly, the relative distribution of ECs between the DA and CV also did not change in controls 
versus Ncx1−/− mutants (Fig. 8B). As the arteriovenous expression pattern of the CV in Ncx1−/− mutants was 
only slightly affected, these data together suggest that there was no redistribution of ECs from the CV to the DA. 
These results therefore support the hypothesis that the Coup-TFII positive cells found in the DA indicate ectopic 
Coup-TFII expression by DA ECs.
Discussion
Our study of the development of the mouse embryonic DA and CV in Ncx1−/− mutants lacking a heartbeat, and 
thus blood flow, reveals an important role for flow in the morphogenesis of this parallel artery and vein pair. Our 
results suggest that flow mediates proper formation of the DA and CV into two separate vessels and prevents the 
development of abnormal fusions between them. Our experiments provide in vivo evidence that flow is essential 
for proper arterial-venous molecular specification of the ECs of the DA, by promoting the acquisition of arterial 
molecular markers and suppressing improper expression of venous markers. In contrast to its role in the DA, flow 
is less important in arterial-venous fate specification of ECs in the CV. We therefore propose a model whereby 
blood flow induces arterial while suppressing venous molecular programming in the DA. In the absence of flow, 
Figure 6. Reduced Notch1 activation in DA ECs in Ncx1−/− mutants. (A–H) Notch1-ICD (N1-ICD) expression 
at 15–17ss in ECs of controls (A,B,E,F) and Ncx1−/− mutants (C,D,G,H) in the DA (A–D) and CV (E-H). 
Green, PECAM-1; Blue, DAPI; Red, Gray, N1-ICD. Scale bar: 25 um. (I) Average Notch1-ICD intensity per EC 
in the DA and CV. *P < 0.05. Average values  ±  s.d. are shown; n = 3 embryos per genotype.
Figure 7. Expression of the venous marker Coup-TFII in Ncx1−/− mutants. (A–H) Coup-TFII expression at 
15–17ss in ECs of controls (A,B,E,F) and Ncx1−/− mutants (C,D,G,H) in the CV (A–D) and DA (E–H). Red, 
PECAM-1; Blue, DAPI; Green, Coup-TFII. Scale bar: 25 um. (I) Proportion of Coup-TFII positive ECs in the 
DA and CV. *P < 0.05, **P < 0.01. Average values  ±  s.d. are shown; n = 4 embryos per genotype.
www.nature.com/scientificreports/
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the expression of arterial markers was lost, whereas expression of venous markers was increased in DA ECs. This 
abnormal arterial-venous marker expression pattern more closely resembles the pattern in CV ECs. These molec-
ular defects may contribute to the failure of proper DA and CV separation and the presence of fusions between 
the two vessels.
Imaging the vasculature in whole-mount embryos by two-photon imaging allowed for a high-resolution 
three-dimensional reconstruction of the DA and CV and detailed examination of their morphology and struc-
ture. Using this method, we could investigate the role of blood flow on DA and CV formation by examining 
embryos mutant for Ncx1, which leads to a lack of heartbeat and thus blood flow without affecting the cells of the 
vasculature directly. These analyses suggest that flow is critically required to ensure that the DA and CV develop 
as two separate vessels, and do not develop abnormal fusions between them. Our finding proposes for the first 
time that blood flow is required for proper formation of paired artery and vein during mammalian vascular 
morphogenesis.
Our work also suggests that flow is required for the development of the normal caliber of the DA. We found 
that the Ncx1−/− mutant DA had an irregular diameter, with certain regions wider and other regions narrower 
throughout the length of the vessel. This finding is consistent with that from a previous study on a mutant in the 
striated muscle protein titin, which has defects in heartbeat and delayed blood flow that also leads to an irregular 
DA6. Together, the results from both studies suggest that the irregular DA phenotype is indeed a consequence 
of the lack of flow. Our current study further shows that the regions with a wider DA are regions of DA and CV 
fusion. Thus, our work shows for the first time that flow is essential for the development of both the DA and CV, 
preventing fusions between the two vessels.
Our study uncovers a crucial role of blood flow in the proper arterial specification of DA ECs. In the absence 
of blood flow, the DA did not exhibit expression of the arterial markers EfnB2GFP and Cx40. Consistent with this 
result, expression of Cx40 in the DA has also been shown to be abolished when blood flow was physically ablated 
ex vivo and embryos were subsequently grown in culture1. Furthermore, we found that expression of these arterial 
markers increased in somite stages following the onset of blood flow, in a flow-dependent manner, suggesting 
that flow may act as a signal that contributes to the acquisition of arterial fate by DA ECs in early development.
Notch signaling plays an important role in arterial fate specification, including in ECs of the DA17,19,23. In 
Ncx1−/− mutants, we found that Notch1 activation decreased in DA ECs. This finding is consistent with an earlier 
study showing loss of Notch1 mRNA in the DA in embryos where blood flow was physically ablated24. Our finding 
on Notch1 activation in developing embryos in utero, together with that of Notch1 mRNA in embryos cultured 
ex vivo, lead us to conclude that blood flow is required to increase Notch signaling in the DA to promote arterial 
fates.
In addition to its role in promoting arterial fate in the DA, our analysis of Ncx1−/− mutants also shows for 
the first time that blood flow suppresses the expression of the venous marker Coup-TFII in DA ECs. Previous 
studies of embryos lacking blood flow in the mouse have not reported the expression of venous fate markers. 
However, in the yolk sac of the chick, ligation of the vitelline artery and subsequent blockade of arterial flow leads 
to ectopic expression of a number of venous markers, including Coup-TFII, along with downregulation of arterial 
markers28,29. Therefore, we believe that blood flow plays a role in promoting arterial and suppressing venous fate 
specification in DA ECs.
Blood flow is crucially important for arterial-venous fate specification in DA ECs, but appears to play less of a 
role in the CV. In the absence of flow, arterial markers, including Notch1, ephrin-B2, and Cx40 in CV ECs remain 
unexpressed, whereas expression of the venous marker Coup-TFII is mildly affected. This suggests that blood flow 
likely affects arterial-venous specification in CV ECs to a lesser extent than it does in DA ECs. One possible cause 
Figure 8. No significant differences were found in the number or distribution of ECs in Ncx1−/− mutants. (A) 
Average number of ECs per vessel section in the DA and CV. (B) Distribution of ECs between the DA and CV. 
Average values  ±  s.d. are shown; n = 4 embryos per genotype.
www.nature.com/scientificreports/
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for this difference is that flow rates and hemodynamic forces in the CV may be lower than those found in the DA. 
Indeed, such a difference has been measured at this stage in the developing yolk sac, where flow rates in veins were 
found to be >2x less than those in arteries30.
The precise mechanism by which blood flow ensures proper separation of the DA and CV is not completely 
understood. Our study suggests a potential mechanism, whereby blood flow promotes arterial-venous specifica-
tion of DA ECs, which then ensures DA and CV separation during development. In the absence of flow, DA ECs 
lose arterial and gain ectopic venous marker expression, giving them a molecular profile more similar to that of 
CV ECs. This lack of molecular differentiation between DA and CV ECs may ultimately be responsible for their 
failure to properly separate or remain separated during development, leading to fusions between the two vessels. 
In support of this notion, a previous study has examined mutants in Notch1 and EfnB2, two of the genes which 
showed reduced or absent expression in the DA in the absence of blood flow. Although these mutants had several 
defects, including changes in the size of the DA, they also contained arterial-venous shunts between the DA and 
the venous circulation, supporting the idea that loss of arterial DA EC fate can lead to fusions between the two 
vessels21.
EC polarity and directed cell movement have also been shown to play important roles during blood vessel 
formation, as the direction of EC movement within a vessel is sensitive to the rate and direction of flow. By using a 
computational model to calculate blood flow and shear stress forces in the vasculature of the developing postnatal 
retina31, others have shown showed that ECs are polarized against the simulated direction of flow, and that the 
strength of polarization is correlated with vessel-wall shear-stress levels. Another recent study using live imaging 
of the yolk sac vasculature found that ECs in arterial vessels migrate towards regions of greater vessel diameter 
against the direction of flow, as well as from vessels experiencing low blood flow velocities into those with high 
flow velocities30. It is therefore possible that in the absence of blood flow in the Ncx1−/− mutant, aberrant EC 
polarity and EC movement may underlie the abnormal fusions between the DA and CV. Together, blood flow and 
proper arterial-venous EC specification may affect polarity and directed cell movement, which are crucial for the 
morphogenesis of the developing DA and CV.
Materials and Methods
Mice. Ncx1lacZ mice11, kindly provided by Dr. Simon J. Conway, and EfnB2-H2BGFP mice26, have been 
described previously. Mice used in this study were kept in a mixed genetic background. All experimental proto-
cols were approved by the University of California, San Francisco Institutional Animal Care and Use Committee, 
and all experimental methods were carried out in accordance with the approved protocols.
Immunofluorescence staining. Embryo harvest, processing, and immunostaining were performed as 
described20,32. Briefly, for whole-mount staining, embryos were dissected and fixed with 4% paraformaldehyde 
overnight at 4°, washed in PBS, and incubated in blocking solution (5% donkey serum and 0.1% Triton X-100 
in PBS). After blocking, embryos were incubated in primary antibodies, washed, and incubated in secondary 
antibodies. All incubations were carried out for 12 h at 4° with rocking. After serial dehydration in 25, 50, 75, and 
100% ethanol at 30-minute intervals, embryos were then cleared in methylsalicylate before imaging.
For frozen sections, embryos were fixed in 4% paraformaldehyde for 20 minutes on ice, embedded in OCT, 
and sectioned. Sections were blocked in 5% donkey serum and 0.2% Triton X-100 in PBS for 1 hour at room 
temperature. They were then incubated with primary antibody in blocking solution overnight at 4°, washed, 
incubated in secondary antibody for 1 hour at room temperature, and mounted in DAPI-containing Vectashield 
(Vector Laboratories).
The following primary antibodies were used: rat anti-CD31 (1:200; 550274, BD Biosciences), goat 
anti-Connexin-40 (1:2000; sc-20466, Santa Cruz Biotechnology), mouse anti-Coup-TFII (1:100; PP-H7147–00, 
R&D Systems). Secondary antibodies were: donkey anti-rat IgG Alexa488 (Invitrogen), donkey anti-goat IgG 
Alexa555 (Invitrogen), donkey anti-rat IgG Cy3 (Jackson Immunoresearch), and donkey anti-mouse IgG Cy5 
(Jackson Immunoresearch). All secondary antibodies were used at 1:500.
Images were acquired on a Zeiss Axiovert2 Plus microscope or custom-built two-photon microscope (see 
below) and analyzed with ImageJ and Imaris (Bitplane).
Two-photon microscopy and image analysis. Images were acquired using a locally constructed 
two-photon microscope33. Whole-mount embryos were imaged by acquiring stacks of planar images with 1 μm 
spacing along the optical axis. The data were reconstructed in three dimensions and analyzed with Imaris soft-
ware (Bitplane Scientific Software).
Quantification of antibody staining and expression. Sections (10 μm) taken from the region of the 
embryo from the top of aortic arch to the region where the CV merges with the common cardinal vein were 
analyzed. To quantify staining intensities, captured images were exported as 16-bit TIFF files and analysis was 
performed in ImageJ. For EfnB2GFP-H2BGFP, DAPI-positive nuclei in CD31-labeled cells of the DA or CV were 
identified and the corresponding staining intensity was determined. To control for variation between embryos, 
the intensity for each cell was normalized against the average value of the five lowest cell intensities in either the 
DA or the CV in the corresponding embryo. A normalized GFP intensity of 2.5 or higher was scored as positive. 
For Cx40, the PECAM1 positive region of the DA or CV was determined by thresholding, and average stain-
ing intensity in this region was measured and normalized against tissue background. For Coup-TFII, cells were 
scored as positive or negative by visual inspection.
Statistical analysis. Values are expressed as mean ± s.d. The two-tailed Student’s t-test was used for com-
parisons between two groups except for Fig. 5 when an ANOVA test was used and specified in the figure legend. 
P < 0.05 was considered significant.
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